Baxter Healthca Patent-Cliff Exposure & CMS Drug Spending Portfolio
Baxter Healthca (US): 74 reconciled FDA prescription therapies, $936.1M 2024 CMS Part D & Medicaid spend, and 16 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 74 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2035-01-01 |
| 2024 CMS Total Public Spend | $936.1M |
| 2024 Medicare Part D Spend | $41.0M |
| 2024 Medicaid Spend | $895.1M |
| California HCAI SB 17 Filings | 16 WAC filings (max 88.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Baxter International across sibling Meru public-data platforms.